The trouble with conventional tools is well documented. Two-dimensional cell cultures, such as the widely used B16F10 mouse melanoma line, are accessible and highly pigmented but do not capture the molecular heterogeneity of human disease. Human melanoma lines like the Sk-Mel series, MNT-1, and A375 offer more relevant genetics but remain simplified. Primary melanocytes isolated from skin biopsies behave more like cells in the body but survive only a limited number of passages before senescence. Animal models—mice, zebrafish, the frog Xenopus laevis, guinea pigs, swine, chick embryos, and fruit flies—each bring valuable features, from the optical clarity of zebrafish embryos to the tyrosinase-dependent, MITF-independent melanin deposition in Xenopus, but they suffer from divergent protein–protein interactions, species-specific genetics, high costs, and mounting ethical constraints. Most critically, identical visible pigmentation phenotypes in humans can arise from entirely distinct molecular disruptions, a depth of heterogeneity that flat cultures and cross-species models frequently miss, leading to inconsistent and unpredictable therapeutic responses.

The review, published in Bioengineering & Translational Medicine, organizes the emerging alternative into three converging categories unified by the iterative Design-Build-Test-Learn engineering cycle. The first is classical synthetic biology: direct genetic and metabolic rewiring using tools such as CRISPR-Cas9, TALENs, and heterologous microbial expression. CRISPR-Cas9, adapted from a bacterial immune system, uses a guide RNA to direct the Cas9 endonuclease to a precise DNA target, where the resulting break is repaired by non-homologous end joining or homology-directed repair. Researchers have exploited this to build exquisitely controlled disease models: knocking out SIRT1 in murine melanoma cells suppresses melanogenesis by reducing MITF expression through altered p38 and ERK signaling, creating a hypopigmentation model relevant to vitiligo, whereas ablating SIRT7 upregulates melanin production via MITF and its downstream enzymes, mimicking melasma and lentigines. In a striking proof of concept, CRISPR was used to correct the T373K missense mutation that abolishes tyrosinase activity in oculocutaneous albinism, restoring enzyme function and melanin content in an animal model and establishing a precise genotype-to-phenotype platform with implications for somatic gene therapy.

Delivery remains the central obstacle to translating these edits into clinic-ready treatments, because the stratum corneum aggressively blocks large molecular cargos and viral vectors carry limited capacity and immunogenic risks. Recent bioengineering work points toward non-viral solutions. A polyamine-modified thermosensitive hydrogel, liquid at refrigerator temperature but gelling at body temperature, has successfully delivered CRISPR-Cas9 ribonucleoproteins through the skin, achieving a 46 percent gene mutation frequency in vivo with no systemic toxicity. Complementary ex vivo strategies—correcting a patient’s own skin cells in the laboratory, expanding them as epidermal sheets, and grafting them back—offer a path to durable, safety-validated gene correction for genetic skin disorders. TALENs, which pair a DNA-binding domain with a FokI nuclease, add a second editing option with lower off-target risk, as demonstrated by disrupting the slc24a5 gene in tuna to produce hypopigmentation.

The second category, heterologous expression systems, swaps slow mammalian kinetics for engineered microbes, transforming melanin from a scarce biological product into an industrially manufacturable biomaterial. The standout example is the marine bacterium Vibrio natriegens, which doubles roughly every ten minutes; when engineered to express a prokaryotic tyrosinase from Bacillus megaterium and supplemented with L-tyrosine and copper, it generates visible melanin within fifteen minutes and saturates the culture within two hours. The same platform demonstrated optogenetic control, using blue light to derepress tyrosinase expression with reversible, spatially precise timing. Parallel efforts in Escherichia coli express tyrosinases such as melA from Rhizobium etli or route flux through the hppd gene to produce pyomelanin, while modular co-expression of multiple enzymes yields non-natural variants like melanin-diamine complexes optimized for fabric dyeing. Eukaryotic hosts fill the gap where post-translational modification matters: the yeast Yarrowia lipolytica secretes pyomelanin with photoprotective and antioxidant properties suitable for dermatological formulations, retaining the glycosylation machinery that bacteria lack.

The third and physiologically richest category comprises biomimetic systems that recreate the dynamic microenvironment of living skin. Co-culturing primary melanocytes and keratinocytes from vitiligo patients produces a patient-specific platform whose drug responses differ markedly from healthy controls—resistant to melanogenic stimulators and hypersensitive to inhibitors—making it a predictive preclinical proxy. Three-dimensional melanocyte spheroids rescue the melanin production that flat monolayers lose, and when treated with the skin-lightening compound fucoxanthin they outperform commercial tissue equivalents in sensitivity. Perhaps most impressive are microfluidic skin-on-a-chip devices: one bilayer-hydrogel platform, perfused with circulating 17β-estradiol and tuned oxygen gradients, reproduces the exact hyperpigmentation patterns of pregnancy-induced melasma, demonstrating that hormone-driven disorders can now be modeled outside the body. Skin explants preserved in gravity-driven, pumpless chips maintain viability for clinical monitoring and personalized testing.

At the macroscopic end of the spectrum, 3D bioprinting and reconstructed human pigmented skin (RHPS) and epidermis (RHPE) models bring structural fidelity to high-throughput screening. Printed bioinks containing live cells and gelatin-alginate matrices are cross-linked, cultured submerged, and then shifted to an air-liquid interface, where exposure to air forces keratinocytes to differentiate and stratify into a viable, keratinized epidermis. Commercial systems such as MelanoDerm, EpiSkin, SkinEthic, and EpiDerm, built from melanocytes and keratinocytes of diverse genetic ancestries, already support safety testing accepted by regulators for dermal irritation and phototoxicity under New Approach Methodologies aligned with the 3Rs of animal research. Pushing to the sub-cellular scale, researchers have engineered artificial melanosomes—tyrosinase encapsulated in lipid vesicles or polymersomes—that synthesize melanin only when triggered by ultraviolet light or that migrate to the perinuclear region of keratinocytes, mimicking the DNA-shielding nuclear caps of native melanosomes. Stem cell technologies extend the vision toward regenerative medicine, with induced pluripotent stem cell–derived melanocytes and MUSE cells integrating into the basal layer of skin organoids without tumorigenic risk.

Complementing all of these live systems are cell-free assays that strip melanogenesis down to its isolated biochemistry. Simple tyrosinase assays using L-DOPA remain a gold standard for rapid inhibitor screening, and they delivered a definitive mechanistic answer in the case of plumbagin, confirming it as a direct enzymatic inhibitor rather than an upstream regulator. More advanced transcription-translation (TXTL) systems can synthesize melanogenic proteins entirely outside living cells, sidestepping host toxicity and metabolic competition. These reductionist platforms are exceptionally reproducible but deliberately blind to membrane permeability and cellular feedback loops, so their findings must be validated in more complex biomimetic models. Emerging cell-free regenerative approaches—platelet-rich plasma, extracellular vesicles, and stem cell secretomes—may bypass transplantation risks altogether by stimulating resident melanocyte precursors and countering oxidative stress in disorders such as vitiligo.

The review is candid about remaining gaps. Engineered microbes are scalable but poorly represent human melanocyte biology; biomimetic constructs are physiologically faithful but expensive, hard to standardize, and still lack immune, vascular, and neural components. CRISPR faces off-target effects, immune recognition of bacterial Cas9, and delivery challenges in continuously renewing skin, prompting development of high-fidelity variants and anti-CRISPR safeguards. Engineered live therapeutics fall under strict regulatory oversight, and industrial melanin production demands biosafety containment and genetic safeguards against environmental release. Yet the trajectory is clear: by unifying programmable gene circuits, engineered microbes, printed tissue, organ-on-chip microenvironments, and synthetic organelles under shared engineering principles, researchers are replacing unpredictable and ethically constrained models with controllable biosystems. The payoff spans next-generation diagnostics, targeted therapies for vitiligo and melasma, biologically integrated sunscreens, antioxidant delivery vehicles, melanin-based radiometal sorbents for nuclear medicine, and even organic semiconductors—a breadth that positions engineered pigmentation platforms as one of the most versatile toolkits in modern dermatology.

Subject of Research: Engineered synthetic biology and biomimetic platforms for studying melanogenesis and pigmentation disorders

Article Title: Engineered platforms for melanogenesis research: Bridging synthetic biology, bioengineering, and biomimetics

Article References: Engineered platforms for melanogenesis research: Bridging synthetic biology, bioengineering, and biomimetics. (n.d.). https://doi.org/10.1002/btm2.70159

Image Credits: AI Generated

DOI: 10.1002/btm2.70159

Keywords: melanogenesis, melanin, synthetic biology, CRISPR-Cas9, biomimetics, 3D bioprinting, skin-on-a-chip, artificial melanosomes, heterologous expression, vitiligo, melasma, reconstructed human skin